Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Other Accumulated Expenses (2018 - 2023)

Historic Other Accumulated Expenses for Dna X (SONM) over the last 6 years, with Q3 2023 value amounting to $260000.0.

  • Dna X's Other Accumulated Expenses rose 18260.87% to $260000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $260000.0, marking a year-over-year increase of 18260.87%. This contributed to the annual value of $171000.0 for FY2022, which is 4985.34% down from last year.
  • Per Dna X's latest filing, its Other Accumulated Expenses stood at $260000.0 for Q3 2023, which was up 18260.87% from $166000.0 recorded in Q2 2023.
  • Dna X's Other Accumulated Expenses' 5-year high stood at $6.8 million during Q2 2022, with a 5-year trough of $16000.0 in Q1 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $279000.0 (2022), whereas its average is $953400.0.
  • Over the last 5 years, Dna X's Other Accumulated Expenses had its largest YoY gain of 18260.87% in 2023, and its largest YoY loss of 9755.88% in 2023.
  • Quarter analysis of 5 years shows Dna X's Other Accumulated Expenses stood at $851000.0 in 2019, then tumbled by 36.66% to $539000.0 in 2020, then crashed by 36.73% to $341000.0 in 2021, then crashed by 49.85% to $171000.0 in 2022, then soared by 52.05% to $260000.0 in 2023.
  • Its last three reported values are $260000.0 in Q3 2023, $166000.0 for Q2 2023, and $16000.0 during Q1 2023.